New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
From JAMA Medical News · · 22 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content:
- A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026